Navigation Links
Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2013 Sales And EPS Of $675 Million And $1.01, Respectively, Both Record Quarterly Highs. Reaffirms Full Year 2013 Diluted Adjusted EPS Outlook Of $4.10 To $4.20.
Date:4/25/2013

re information about Sigma-Aldrich, please visit the website at www.sigma-aldrich.com.

Non-GAAP Financial Measures:  The Company supplements its disclosures made in accordance with accounting principles generally accepted in the United States (U.S. GAAP) with certain non-GAAP financial measures.  The Company does not, and does not suggest investors should, consider such non-GAAP financial measures in isolation from, or as a substitute for, GAAP financial information.  These non-GAAP measures may not be consistent with the presentation by other companies inside or outside of the Company's industry.  Whenever the Company uses such non-GAAP measures, it provides a reconciliation of such measures to the most closely applicable GAAP measure.  See the Supplemental Financial Information on pages 10 and 11 for these reconciliations.

With over 60% of sales denominated in currencies other than the U.S. dollar, management uses currency adjusted sales growth when analyzing Company performance, and believes it is useful as well to investors to judge the Company's performance.  Organic sales growth data presented in this release excludes currency and acquisitions impacts.  The Company calculates the impact of changes in foreign currency exchange rates by multiplying current period activity by the difference between current period exchange rates and prior period exchange rates.  The result is the defined impact of "changes in foreign currency exchange rates."  While we are able to report past currency impacts, we are unable to estimate changes that may occur later in 2013 to applicable exchange rates.  Any significant changes in currency exchange rates would likely have a significant impact on reported growth rates due to the volume of sales denominated in foreign currencies.

Management also uses the following non-GAAP measures to judge its performance and ability to&
'/>"/>

SOURCE Sigma-Aldrich
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Sigma-Aldrich Announces Q1 2013 Earnings Conference Call
2. Sigma-Aldrich Corporations Sigma Life Science Business to Distribute Worldwide Olink Biosciences Protein Interaction Analysis Technology
3. Sigma-Aldrich Reports Record Full Year 2012 Results. Reports Q4 2012 Diluted EPS Of $0.96. Q4 2012 Sales Increased 7%. Full Year 2012 Adjusted Diluted EPS Was $3.85. Expects Full Year 2013 Adjusted Diluted EPS To Increase To $4.10 - $4.20.
4. Sigma-Aldrich Aligns Into Three New Market-Focused Business Units
5. Sigma-Aldrich (NASDAQ: SIAL) Declares $0.20 Quarterly Dividend
6. Sigma-Aldrich Enhances Customer Focus in China - Unveils Dynamic New Website and Expands Product Offering Through Vetec Brand
7. Sigma-Aldrich Corporation To Present At Upcoming Investor Conferences
8. Sigma-Aldrich Accelerates Analytical Research and Extends Benefits of Fused-Core Particle Technology to All HPLC Users with the Launch of New Ascentis Express 5 Micron Particle by Supelco
9. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
10. Morgan & Morgan Announces Investigation of MAP Pharmaceuticals (NASDAQ: MAPP)
11. SHAREHOLDER ALERT: Morgan & Morgan announces an investigation of Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) and whether senior management and the board of directors violated fiduciary duties owed to Vertex shareholders.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... , Feb. 27, 2015  Following a bipartisan ... that moved H.R. 284, the Medicare DMEPOS Competitive ... Association for Homecare (AAHomecare) released a statement praising ... to pass the legislation. "Today,s mark-up ... House Ways and Means Committee is a critical ...
(Date:2/27/2015)... HOUSTON, TX , Feb. 27, 2015 ... EPI) and Bloom Burton & Co. Ltd. ("Bloom Burton") ... lock-up (the "Lock-Up") 2,353,130 common shares of the Company ... subject to the Lock-Up. Of the Common Shares released ... immediately upon release from the Lock-Up while the remainder ...
(Date:2/27/2015)...   Synageva BioPharma Corp. (Synageva) (NASDAQ: ... therapeutic products for rare diseases, joins the National ... for Rare Diseases™ (EURORDIS™), The Global Genes Project™, ... Disease Day. On the last day ... other participants conduct special events to raise awareness ...
Breaking Medicine Technology:Bidding Fix Takes Major Step Forward After Bipartisan Vote of House Ways and Means Committee 2ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 2ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 3ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 4Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 2Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 3Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 4Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 5Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 6
... with investigators worldwide to develop new treatments for ... diverse forms of cancer - Plenary ... of patients with early-stage breast cancer, - Four oral sessions to feature ... study in renal cell ...
... Hispanics/Latinos, People ... with Diabetes and Obese Individuals, PARSIPPANY, N.J., ... presented at the American Society of,Hypertension,s Twenty- Third Annual ... powerful combination drug AZOR(TM),(amlodipine and olmesartan medoxomil) safely and ...
Cached Medicine Technology:Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 2Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 3Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 4Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 5Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 6Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 7Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 8Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 9Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 10Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 2Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 3Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 4Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 5Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 6Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 7
(Date:2/28/2015)... “ Powermod ” was featured on NewsWatch as part ... the latest and coolest technology products and services available to ... technology expert, conducted the review and shared with viewers how ... stuck with a low battery and no way to charge ... on a daily basis. Even when a person does have ...
(Date:2/28/2015)... Memphis, TN: MedixSafe has retracted a previous announcement ... reader named Guardian 2. The correct product name ... scanner that significantly increases the complexity of security ... scanner provides fast and easy access for both ... lockers with Vanguard technology tracks inventory by ...
(Date:2/28/2015)... 28, 2015 My Shiney Hiney® LLC., the ... team to Las Vegas, Nevada for the annual ASD Market ... of the leading consumer-goods tradeshows and My Shiney Hiney will ... event. My Shiney Hiney can be found at booth number ... for the at-home personal hygiene brush and cleansing system exclusively ...
(Date:2/27/2015)... 27, 2015 Hispanics develop alcoholic liver ... four and 12 years earlier than Whites/Caucasians or African ... Health System. , While previous research indicated that Hispanics ... the new study -- published online in the journal ... be the first to pinpoint racial and ethnic disparities ...
(Date:2/27/2015)... OnChip Devices , a world leader ... bondable, silicon ESD (Electrostatic Discharge) protection diodes targeted for ... ESD88NP and ESD88PN are designed to ... IC products. These Zeners exhibit no device degradation ... meet the requirements of IEC61000 and safely dissipate ESD ...
Breaking Medicine News(10 mins):Health News:Solutions to Keep Phones Charged were Featured on NewsWatch Television on January 29, 2015 2Health News:New Name Announced For Newest MedixSafe Readers – MedixSafe Vanguard 2Health News:My Shiney Hiney® to Participate in ASD Market Week 2015 2Health News:UC Davis Study Finds Hispanics Develop Alcoholic Liver Disease at Younger Ages than Caucasians or African Americans 2Health News:OnChip Introduces New Series of Space Saving Bare-die Zener Diodes for Transient Voltage Suppression 2Health News:OnChip Introduces New Series of Space Saving Bare-die Zener Diodes for Transient Voltage Suppression 3
... time , , TUESDAY, Jan. 15 (HealthDay News) -- Foodborne illness can ... different pathogens. Here is a rundown of the most common bacterial ... E. COLI 0157:H7 , There are many strains ... coli. Most are harmless, four or five can cause disease, and ...
... drinks containing live bacteria, have a tangible effect on the ... today (Tuesday 15 January) in the journal Molecular Systems Biology. ... at how probiotics change the biochemistry of bugs known as ... an important part in a persons metabolic makeup. Different people ...
... Integrated Solutions Help Dearborn County Hospital Better Serve ... Area with Heightened Productivity and Collaboration, ... Dearborn County Hospital,in southeast Indiana, efficient yet responsive ... patients and patient,families. To boost care levels even ...
... Postmenopausal women who take combined estrogen/progestin hormone-replacement ... fourfold increased risk of developing various forms of ... researchers at Fred Hutchinson Cancer Research Center., Previous ... combined hormone-therapy use was necessary to increase overall ...
... feedback feature promotes a more informed health care ... and regional studies,indicate that informed patients make better ... is launching a member feedback feature in,Spring 2008 ... to share,information with each other about their provider ...
... Rivers,Pharmaceuticals, LLC finalized acquisition of the hepatitis C ... ). Valeant is,receiving $91 million from Three Rivers ... growing portfolio is very exciting," said,Donald J. Kerrish, ... purchase is only a beginning for Three Rivers, ...
Cached Medicine News:Health News:U.S. Food Safety: Foodborne Illnesses a Menu for Disaster 2Health News:U.S. Food Safety: Foodborne Illnesses a Menu for Disaster 3Health News:U.S. Food Safety: Foodborne Illnesses a Menu for Disaster 4Health News:Probiotics affect metabolism, says new study 2Health News:Tri-State Hospital to Gain Greater Efficiency and Responsiveness in Delivering Patient Care with Siemens Open Communications Solutions 2Health News:Tri-State Hospital to Gain Greater Efficiency and Responsiveness in Delivering Patient Care with Siemens Open Communications Solutions 3Health News:Tri-State Hospital to Gain Greater Efficiency and Responsiveness in Delivering Patient Care with Siemens Open Communications Solutions 4Health News:Tri-State Hospital to Gain Greater Efficiency and Responsiveness in Delivering Patient Care with Siemens Open Communications Solutions 5Health News:Combined HRT increases risk of lobular breast cancer fourfold after just 3 years of use 2Health News:Regence Enables Members to Share Feedback With Each Other When Researching Health Care Provider Options 2Health News:Three Rivers Pharmaceuticals(R), LLC Acquires Hepatitis C Drug Infergen(R) from Valeant Pharmaceuticals 2
Inquiry 4Fr, 5Fr and 6Fr diagnostic electrophysiology catheters offer simple, precise distal control with it's patented Easy-Hand steering mechanism....
... offers patient monitoring products for hospital ... medium acuity monitoring. The Envoy patient ... The Enmove monitor offers a ... complement the Envoy. The Ensemble ...
... The Mayfield Triad Skull Clamp, compatible with ... visual indication of clamping force on all ... user with the possibility of adjusting the ... can easily be increased or decreased by ...
Protein-to-creatinine ratio is key to earlier detection of Kidney Disease...
Medicine Products: